GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » ROC %

OPHLY (Ono Pharmaceutical Co) ROC % : 10.02% (As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Ono Pharmaceutical Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Ono Pharmaceutical Co's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was 10.02%.

As of today (2024-12-13), Ono Pharmaceutical Co's WACC % is 3.34%. Ono Pharmaceutical Co's ROC % is 13.65% (calculated using TTM income statement data). Ono Pharmaceutical Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Ono Pharmaceutical Co ROC % Historical Data

The historical data trend for Ono Pharmaceutical Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ono Pharmaceutical Co ROC % Chart

Ono Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.28 13.31 13.14 17.72 18.98

Ono Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.09 21.29 9.69 13.87 10.02

Ono Pharmaceutical Co ROC % Calculation

Ono Pharmaceutical Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2024 is calculated as:

ROC % (A: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2023 ) + Invested Capital (A: Mar. 2024 ))/ count )
=1067.531 * ( 1 - 21.8% )/( (4614.388 + 4180.315)/ 2 )
=834.809242/4397.3515
=18.98 %

where

Invested Capital(A: Mar. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6601.89 - 758.385 - ( 1229.117 - max(0, 919.685 - 2581.849+1229.117))
=4614.388

Invested Capital(A: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6098.495 - 552.562 - ( 1365.618 - max(0, 691.663 - 2760.645+1365.618))
=4180.315

Ono Pharmaceutical Co's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=704.844 * ( 1 - 21.18% )/( (0 + 5541.887)/ 1 )
=555.5580408/5541.887
=10.02 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7319.879 - 510.913 - ( 1267.079 - max(0, 872.029 - 2807.966+1267.079))
=5541.887

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ono Pharmaceutical Co  (OTCPK:OPHLY) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Ono Pharmaceutical Co's WACC % is 3.34%. Ono Pharmaceutical Co's ROC % is 13.65% (calculated using TTM income statement data). Ono Pharmaceutical Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Ono Pharmaceutical Co ROC % Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ono Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a world-wide business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.